Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males-Reference-Cited by-同舟云学术

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males

Published:2011-02-01 Issue:3 Volume:71 Page:429-436
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Herman Gary A.,Mistry Goutam C.,Yi Bingming,Bergman Arthur J.,Wang Amy Q.,Zeng Wei,Chen Li,Snyder Karen,Ruckle Jon L.,Larson Patrick J.,Davies Michael J.,Langdon Ronald B.,Gottesdiener Keith M.,Wagner John A.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2010.03852.x/fullpdf

Reference27 articles.

1. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin;Herman;Clin Pharmacol Ther,2007

2. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes;Herman;J Clin Endocrinol Metab,2006

3. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

4. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials;Karasik;Curr Med Res Opin,2008

5. Sitagliptin;Lyseng-Williamson;Drugs,2007

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson’s disease;GeroScience;2024-04-02

2. Sitagliptin elevates plasma and CSF incretin levels following oral administration to nonhuman primates: relevance for neurodegenerative disorders;GeroScience;2024-03-27

3. Reduced blood glucose levels by the combination of vadadustat in an elderly patient with chronic kidney disease who was receiving mitiglinide and sitagliptin: a case report;Journal of Pharmaceutical Health Care and Sciences;2023-12-11

4. A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor;Diabetes, Obesity and Metabolism;2023-11-12

5. Pharmacovigilance study of the association between dipeptidyl peptidase–4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS);Scientific Reports;2022-07-30